Your Vision Loss May Have a Genetic Name. Here's What to Do.

Your retina is under constant immune surveillance. Complement proteins patrol retinal tissue, cleaning up debris and marking damaged cells for removal. Complement factor H is the brake on this system. It tells complement proteins when to stop attacking healthy cells. Without a functioning CFH brake, complement overfires in the retina, triggering inflammation and damage to the retinal pigment epithelium (the cellular layer that nourishes photoreceptors).

The Y402H variant in CFH is the single strongest genetic predictor of age-related macular degeneration, carried by roughly 30 to 40% of people of European ancestry. If you have this variant, your CFH protein is less effective at controlling retinal inflammation. The complement system stays activated longer. Your retina is essentially under chronic low-level immune attack, even if you have no symptoms yet.

You experience this as slowly dimming central vision, color desaturation, or difficulty reading and recognizing faces. Symptoms often don’t appear until your 60s or 70s, but the genetic damage starts decades earlier. The H allele creates a version of CFH that doesn’t bind as tightly to the retina, leaving more room for complement damage to accumulate.

Your retina has one of the highest metabolic demands of any tissue in your body. Photoreceptors burn oxygen like furnaces. That means blood supply is everything. VEGF is the master signaling molecule that tells your body to grow new blood vessels to feed the retina. Too little VEGF and your photoreceptors starve. Too much VEGF and you get pathological neovascularization, where fragile, leaky vessels proliferate and bleed into the retina.

The -634G>C variant in VEGF shifts this balance in a way that influences your risk of both wet age-related macular degeneration and diabetic retinopathy. Roughly 35% of people carry this variant. If you have the C allele, your retina may be slightly primed toward neovascularization, meaning that in the presence of high blood glucose or retinal inflammation, you’re more likely to develop abnormal new vessels. This variant doesn’t cause disease on its own, but it loads the gun.

You might notice this as waviness in your vision, central dark spots that seem to grow, or a sudden blurring that feels like wet AMD appearing overnight. The progression is much faster in people with uncontrolled diabetes or chronic macular inflammation.

Your photoreceptors are powered by mitochondria, the cellular powerhouses that convert light into electrical signals your brain can understand. This process generates a lot of oxidative stress. Superoxide radicals are constantly being produced as a byproduct of ATP generation. Your cells have an emergency cleanup crew for this: SOD2, the mitochondrial superoxide dismutase. It converts dangerous superoxide radicals into hydrogen peroxide, which then gets converted to water by catalase. If this system fails, oxidative damage accumulates inside the cell, triggering photoreceptor death.

The Val16Ala variant in SOD2 affects how efficiently this enzyme works. Roughly 40% of people are homozygous for the Ala variant, which produces SOD2 protein that is less effective at clearing superoxide. This means your photoreceptors are under higher oxidative stress than they should be, and your retina ages faster at a cellular level. You can’t see this damage happening. It’s happening inside the mitochondria. But over decades, it adds up.

You experience this as gradual, progressive vision dimming that starts in your 50s or 60s, sometimes with difficulty reading small print or noticing objects in your peripheral vision first. The process is painless and often goes unnoticed until vision loss becomes significant.

Vitamin D is not just about bone health. Every cell in your retina has vitamin D receptors (VDR), and activation of these receptors controls inflammation, cell survival, and vascular integrity in retinal tissue. VDR is the translator. It takes circulating vitamin D and tells retinal cells how to behave. Broken translation creates chronic retinal inflammation.

Variants in the VDR gene affect how sensitive your retina is to circulating vitamin D. The FokI polymorphism, in particular, shows two main forms: short form and long form. People with the long form typically need more circulating vitamin D to activate the same amount of VDR signaling in their retinas. Roughly 30 to 40% of people carry the long form, meaning they may be functionally vitamin D deficient even with blood levels that look acceptable. Their retinas stay in a mildly inflammatory state because VDR signaling is persistently weak.

You notice this as vision that declines slowly but steadily, sometimes with an increase in floaters or a vague sense that light is bothering you more than it used to. It’s not dramatic, but it’s relentless.

MTHFR converts dietary folate into the active form your cells use for methylation reactions. Methylation fuels nitric oxide synthesis, which maintains vascular tone and blood flow in the retina. Broken MTHFR means less nitric oxide, worse vascular function, and elevated homocysteine that damages retinal blood vessels from the inside.

The C677T variant reduces MTHFR enzyme efficiency by 40 to 70%, and roughly 40% of people of European ancestry carry at least one copy. If you have this variant, your retina is getting less nitric oxide, and your homocysteine levels are climbing, even if your bloodwork looks normal. Elevated homocysteine is a known risk factor for macular degeneration. It damages the endothelial cells lining retinal capillaries, making them leaky and dysfunctional.

You might notice blurred vision that comes and goes, sensitivity to light, or a vague sense that your vision is declining faster than it should be for your age. Some people describe colors seeming washed out.

APOE determines how your body handles cholesterol and lipids, including in the retina. Your retina is about 60% lipid by dry weight. Myelinated axons, photoreceptor outer segments, and retinal pigment epithelium cells all depend on proper lipid metabolism. APOE3 is the common form. APOE4 is associated with slower cholesterol clearance and more lipid accumulation in tissues, including the retina.

Roughly 25 to 30% of people carry at least one APOE4 allele. If you have APOE4, your retina is more prone to lipid accumulation, which accelerates age-related macular degeneration and increases inflammation in retinal tissue. This is especially problematic if you also carry CFH or VEGF risk variants. The lipid accumulation creates a substrate for complement activation.

You experience this as vision loss that seems to accelerate in your 60s, sometimes with prominent drusen (yellow deposits under the retina) visible on eye exams. Central vision dims faster than expected.